Cargando…

Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis

While the Surviving Sepsis Campaign guidelines recommend an initial target value of 65 mmHg as the mean arterial pressure (MAP) in patients with septic shock, the optimal MAP target for improving outcomes remains controversial. We performed a meta-analysis to evaluate the optimal MAP for patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimoto, Hidero, Fukui, Satoshi, Higashio, Koki, Endo, Akira, Takasu, Akira, Yamakawa, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424848/
https://www.ncbi.nlm.nih.gov/pubmed/36051909
http://dx.doi.org/10.3389/fphys.2022.962670
_version_ 1784778315194695680
author Yoshimoto, Hidero
Fukui, Satoshi
Higashio, Koki
Endo, Akira
Takasu, Akira
Yamakawa, Kazuma
author_facet Yoshimoto, Hidero
Fukui, Satoshi
Higashio, Koki
Endo, Akira
Takasu, Akira
Yamakawa, Kazuma
author_sort Yoshimoto, Hidero
collection PubMed
description While the Surviving Sepsis Campaign guidelines recommend an initial target value of 65 mmHg as the mean arterial pressure (MAP) in patients with septic shock, the optimal MAP target for improving outcomes remains controversial. We performed a meta-analysis to evaluate the optimal MAP for patients with vasodilatory shock, which included three randomized controlled trials that recruited 3,357 patients. Between the lower (60–70 mmHg) and higher (>70 mmHg) MAP target groups, there was no significant difference in all-cause mortality (risk ratio [RR], 1.06; 95% confidence intervals [CI], 0.98–1.16) which was similar in patients with chronic hypertension (RR, 1.10; 95% CI, 0.98–1.24) and patients aged ≥65 years (RR, 1.10; 95% CI, 0.99–1.21). No significant difference in adverse events was observed between the different MAP groups (RR, 1.04; 95% CI, 0.87–1.24); however, supraventricular arrhythmia was significantly higher in the higher MAP group (RR, 1.73; 95% CI, 1.15–2.60). Renal replacement therapy was reduced in the higher MAP group of patients with chronic hypertension (RR, 0.83; 95% CI, 0.71–0.98). Though the higher MAP control did not improve the mortality rate, it may be beneficial in reducing renal replacement therapy in patients with chronic hypertension. Systematic review registration: UMIN Clinical Trials Registry, identifier UMIN000042624
format Online
Article
Text
id pubmed-9424848
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94248482022-08-31 Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis Yoshimoto, Hidero Fukui, Satoshi Higashio, Koki Endo, Akira Takasu, Akira Yamakawa, Kazuma Front Physiol Physiology While the Surviving Sepsis Campaign guidelines recommend an initial target value of 65 mmHg as the mean arterial pressure (MAP) in patients with septic shock, the optimal MAP target for improving outcomes remains controversial. We performed a meta-analysis to evaluate the optimal MAP for patients with vasodilatory shock, which included three randomized controlled trials that recruited 3,357 patients. Between the lower (60–70 mmHg) and higher (>70 mmHg) MAP target groups, there was no significant difference in all-cause mortality (risk ratio [RR], 1.06; 95% confidence intervals [CI], 0.98–1.16) which was similar in patients with chronic hypertension (RR, 1.10; 95% CI, 0.98–1.24) and patients aged ≥65 years (RR, 1.10; 95% CI, 0.99–1.21). No significant difference in adverse events was observed between the different MAP groups (RR, 1.04; 95% CI, 0.87–1.24); however, supraventricular arrhythmia was significantly higher in the higher MAP group (RR, 1.73; 95% CI, 1.15–2.60). Renal replacement therapy was reduced in the higher MAP group of patients with chronic hypertension (RR, 0.83; 95% CI, 0.71–0.98). Though the higher MAP control did not improve the mortality rate, it may be beneficial in reducing renal replacement therapy in patients with chronic hypertension. Systematic review registration: UMIN Clinical Trials Registry, identifier UMIN000042624 Frontiers Media S.A. 2022-08-16 /pmc/articles/PMC9424848/ /pubmed/36051909 http://dx.doi.org/10.3389/fphys.2022.962670 Text en Copyright © 2022 Yoshimoto, Fukui, Higashio, Endo, Takasu and Yamakawa. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Yoshimoto, Hidero
Fukui, Satoshi
Higashio, Koki
Endo, Akira
Takasu, Akira
Yamakawa, Kazuma
Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
title Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
title_full Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
title_fullStr Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
title_full_unstemmed Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
title_short Optimal target blood pressure in critically ill adult patients with vasodilatory shock: A systematic review and meta-analysis
title_sort optimal target blood pressure in critically ill adult patients with vasodilatory shock: a systematic review and meta-analysis
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424848/
https://www.ncbi.nlm.nih.gov/pubmed/36051909
http://dx.doi.org/10.3389/fphys.2022.962670
work_keys_str_mv AT yoshimotohidero optimaltargetbloodpressureincriticallyilladultpatientswithvasodilatoryshockasystematicreviewandmetaanalysis
AT fukuisatoshi optimaltargetbloodpressureincriticallyilladultpatientswithvasodilatoryshockasystematicreviewandmetaanalysis
AT higashiokoki optimaltargetbloodpressureincriticallyilladultpatientswithvasodilatoryshockasystematicreviewandmetaanalysis
AT endoakira optimaltargetbloodpressureincriticallyilladultpatientswithvasodilatoryshockasystematicreviewandmetaanalysis
AT takasuakira optimaltargetbloodpressureincriticallyilladultpatientswithvasodilatoryshockasystematicreviewandmetaanalysis
AT yamakawakazuma optimaltargetbloodpressureincriticallyilladultpatientswithvasodilatoryshockasystematicreviewandmetaanalysis